Oncogenic Viruses: Advances in Molecular Diagnosis, Prevention Strategies and Therapy—2nd Edition

A Special Issue of Pathogens (ISSN 2076-0817) belonging to the section "Viral Pathogens".

Deadline for manuscript submissions: 15 December 2026 | Viewed by 2245

Editor


E-Mail Website
Guest Editor
Department of Microbiology, Faculty of Medicine, University of Medicine and Pharmacy “Grigore T. Popa”, Universitatii St. No. 16, 700115 Iasi, Romania
Interests: HPV; polyomaviruses; HBV; EBV
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The incidence of tumors caused by viruses (e.g., cervical cancer, skin cancer, head and neck cancers, liver cancer, and kidney cancer) is consistent with the global trend of an increasing incidence of cancers more broadly. However, the viral origin of such tumors also results in certain advantages, such as the availability of screening (HPV), personalized targeted therapy (MCV), and prevention by vaccination (HBV, HPV).

With this context in mind, this Special Issue aims to publish both original research and comprehensive reviews that explore recent advances in the development and validation of clinically relevant biomarkers, such as circulating tumor DNA (ctDNA), for tumors driven by human oncogenic viruses (e.g.,  HPV, polyomaviruses, HBV, HCV, and EBV). We welcome studies investigating the utility of these biomarkers in early tumor detection, prognosis, monitoring disease evolution, predicting recurrence, and assessing therapeutic response. Technical harmonization of the assays used for biomarker detection is very important in terms of evaluating the characteristics of these assays and for comparative studies.

We invite researchers working on human oncogenic viruses, as well as those using animal models to study virus-associated tumors or to develop prevention and therapeutic strategies, to contribute their work. Submissions may cover virology, molecular biology, diagnostics, public health, vaccinology, and other related fields.

We look forward to receiving your contributions.

Dr. Ramona Gabriela Ursu
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pathogens is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • oncogenic viruses
  • specific biomarkers
  • early detection
  • targeted therapy
  • monitoring
  • prevention

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Related Special Issue

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

21 pages, 682 KB  
Article
Genotype-Specific HPV E6/E7 mRNA Triage for Risk Stratification in HPV DNA-Positive Women with ASC-US/LSIL: A Population-Based Tromsø Cohort
by Sveinung Wergeland Sørbye, Bente Marie Falang, Mona Antonsen and Elin Richardsen
Pathogens 2026, 15(7), 747; https://doi.org/10.3390/pathogens15070747 - 17 Jul 2026
Viewed by 461
Abstract
HPV DNA-positive women with ASC-US/LSIL cytology constitute a heterogeneous triage group. We evaluated genotype-specific HPV E6/E7 mRNA testing with PreTect HPV-Proofer’7 in a population-based cohort from Tromsø and compared the findings descriptively with a previously published cohort from Bodø. This retrospective quality-assurance study [...] Read more.
HPV DNA-positive women with ASC-US/LSIL cytology constitute a heterogeneous triage group. We evaluated genotype-specific HPV E6/E7 mRNA testing with PreTect HPV-Proofer’7 in a population-based cohort from Tromsø and compared the findings descriptively with a previously published cohort from Bodø. This retrospective quality-assurance study included 1006 HPV DNA-positive women with ASC-US/LSIL cytology screened between 2019 and 2024, with linkage to regional pathology records through 31 December 2025. The assay detects E6/E7 mRNA from HPV16, 18, 31, 33, 45, 52, and 58. ASC-US/LSIL accounted for 42.5% of linked HPV DNA-positive women in Tromsø compared with 22.3% in Bodø. Among the mRNA-tested ASC-US/LSIL cohorts, mRNA positivity was similar (40.8% vs. 44.6%). In Tromsø, CIN2+ was recorded in 26.1% of mRNA-positive and 7.9% of mRNA-negative women (RR 3.31, 95% CI 2.41–4.55), whereas CIN3+ was recorded in 3.9% and 1.0%, respectively (RR 3.88, 95% CI 1.53–9.82). For CIN2+, sensitivity was 69.5%, specificity 64.4%, PPV 26.1%, and NPV 92.1%. Among HPV16/18 DNA-positive women, CIN2+ risk was 42.7% in mRNA-positive and 13.4% in mRNA-negative women. Simulated mRNA-guided referral reduced immediate colposcopy referrals by 59.2%. Genotype-specific mRNA testing provided clinically relevant risk stratification, with directionally similar patterns being observed in the Tromsø and Bodø cohorts; however, mRNA-negative women require structured surveillance. Full article
Show Figures

Figure 1

22 pages, 309 KB  
Article
Kidney Transplant Recipients: Viral Infections and Malignancies
by Costin Damian, Adrian Constantin Covic, Ramona Gabriela Ursu, Aida Corina Badescu, Simona Mihaela Hogas, Andreea Simona Covic, Mihai Isache, Silvia Gabriela Ionescu, Corneliu Morosanu, Stefania Brindusa Copacianu and Luminita-Smaranda Iancu
Pathogens 2026, 15(4), 390; https://doi.org/10.3390/pathogens15040390 - 5 Apr 2026
Cited by 1 | Viewed by 1409
Abstract
Kidney transplant recipients (KTRs) remain vulnerable to infectious complications and malignancies due to chronic immunosuppression, both of which may contribute to allograft dysfunction and adverse clinical outcomes. This study aimed to evaluate the prevalence of viral infections and post-transplant malignancies among hospitalized KTRs [...] Read more.
Kidney transplant recipients (KTRs) remain vulnerable to infectious complications and malignancies due to chronic immunosuppression, both of which may contribute to allograft dysfunction and adverse clinical outcomes. This study aimed to evaluate the prevalence of viral infections and post-transplant malignancies among hospitalized KTRs and to identify factors associated with acute kidney injury (AKI) and chronic graft dysfunction. We conducted a prospective observational study including 215 adult KTRs admitted to a tertiary transplant center over a one-year period. Clinical data, malignancy history, and viral detection for BK polyomavirus (BKV), cytomegalovirus (CMV), Epstein–Barr virus (EBV), and parvovirus B19 were analyzed. AKI occurred in 65.6% of patients, while chronic graft dysfunction was present in 21.4%. Viral positivity was detected in 16.7% of the cohort, most frequently BKV and CMV. Infectious etiologies represented the most common cause of AKI. Viral positivity was significantly associated with infectious mechanisms of AKI and was independently associated with AKI in multivariable analysis (adjusted OR 3.01, p = 0.02). In a separate multivariable model, malignancy history (aOR 9.30), viral positivity (aOR 3.33), and concurrent AKI (aOR 3.42) were independently associated with chronic graft dysfunction. These findings suggest that viral reactivation and malignancy history cluster with clinical states of increased graft vulnerability in hospitalized KTRs. Integrated evaluation of infectious, immunologic, and clinical factors may improve risk stratification and management of transplant recipients presenting with acute illness. Full article
Back to TopTop